PLEASE COMPLETE THIS SECTION FIRST

IRB #: Study Title:

Date of submission of this form: Principal Investigator:

Wyoming Department of Health Institutional Review Board Application for Continuing Review or Study Closure

	rippinouncii communig moment on orang oronan			
	Please complete ALL sections of this form whether applying for Continuing Review or Study Closure.			
1.	STATUS OF THE RESEARCH			
Che	Check the one choice that best describes the current state of this research study:			
	No participants have been enrolled to date.			
	ecruitment and/or enrollment of new participants or review of records/specimens continue.			
	Study is no longer enrolling, but participants still receive research-related interventions, (e.g., still receiving			
	treatment, obtaining blood draws)			
	Study is no longer enrolling and participants have completed research-related interventions. The study remains active <u>only</u> for long-term follow-up.			
	Study enrollment is permanently closed, participants have completed all research-related interventions, and long-term follow-up has been completed. The remaining research activities are limited only to data analysis that may require contact with records or specimens.			
2.	2. CLOSE THE STUDY			
Please provide a final study report, progress reports, and publications to the IRB as they become available.				
	Close the study. Enrollment and follow-up are complete and no further contact with participants/records/specimens is anticipated. Describe the reason for closure (i.e., enrollment goals achieved, reason for early termination):			
3. SUMMARY OF PROGRESS SINCE INITIAL IRB REVIEW OR PREVIOUS CONTINUING REVIEW APPROVAL Record numbers reflective of activities where a WDH investigator is involved in the conduct of the research or is responsible for regulatory reporting (i.e., adverse events, progress reports): Total number of participants approved by WDH IRB Total number of participants consented to participate to date, including withdrawals Total number of participants consented since the previous IRB continuing review approval* Total number of participants that consented but did not complete the study since the previous IRB continuing review approval* (include explanation for each) Provide a description of study activities to date, including any difficulties in recruiting subjects, in the space below:				
Seld	ect one answer for each question: Yes No Since the initial IRB review or previous IRB continuing review approval, have any unanticipated problems involving risks to participants and/or serious, unanticipated and research-related adverse events occurred? If "Yes", attach all written summaries and/or progress reports since previous IRB continuing review approval. Total number of events/problems since initial review or previous IRB continuing review			
4a.	☐Yes ☐No Have these events been reported previously to the IRB?			

IRB #:	Study Title:		
Date of submissio	•	Principal Investigator:	
Date of Submissio	ii oi tilis ioiiii.	i imopai investigator.	
5. □Yes □No	Have any relevant clinical findings, literature, reports or other information (particularly information about risks associated with the research) become available since the last IRB continuing review approval*? If "Yes", please describe:		
6. □Yes □No	Have there been any complair approval*? If "Yes", please de	nts about this research since the last IRB continuing review escribe:	
7. Yes No Have there been any modifications to this research study since the initial IRB review or last IRB continuing review approval*? If "Yes", please answer question 7a. & describe all modifications:			
7a. □Yes □No	Was the IRB notified about the If no please explain why not:	e modifications at the time they were implemented?	
8. Yes No		a written informed consent document for this study? If "Yes", submit ed informed consent document.	
9. INVESTIGATOR'S CONFLICT OF INTEREST STATEMENT			
∐Yes	an economic interest in, or act interests would reasonably ap	sponsible for the design, conduct, or reporting of the research have as an officer or a director of any outside entity whose financial pear to be affected by the research? If "Yes" and the IRB has not er to the IRB describing the conflict immediately.	
10. CONTACT INFORMATION Principal Investigator's e-mail address:			
Phone #:	Fax #:	Pager #:	
Study contact name (if different than PI):			
Study contact e-mail address:			
		Pager #:	
. ποπο π.	1 ax #	1 agoi #	
retained in my files for	or every participant enrolled in this n was required). I also confirm tha	rent IRB-approved consent form has been signed, dated, and is study and a copy was provided to the person who signed the form (if it no changes to study procedures or the consent form(s) were initiated	
Principal Investigato	or's Signature	 Date	